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Activating mutations in KRAS are among the most
frequent events in diverse human carcinomas and
areparticularly prominent in humanpancreatic ductal
adenocarcinoma (PDAC). An inducible KrasG12D-
driven mouse model of PDAC has established a crit-
ical role for sustained KrasG12D expression in tumor
maintenance, providing a model to determine the
potential for and the underlying mechanisms of
KrasG12D–independent PDAC recurrence. Here, we
show that some tumors undergo spontaneous
relapse and are devoid of KrasG12D expression and
downstream canonical MAPK signaling and instead
acquire amplification and overexpression of the
transcriptional coactivator Yap1. Functional studies
established the role of Yap1 and the transcriptional
factor Tead2 in driving KrasG12D-independent tumor
maintenance. The Yap1/Tead2 complex acts cooper-
atively with E2F transcription factors to activate a
cell cycle and DNA replication program. Our studies,
alongwith corroborating evidence fromhumanPDAC
models, portend a novel mechanism of escape from
oncogenic Kras addiction in PDAC.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) remains a largely
incurable lethal disease with a median survival of 6 months(Hidalgo, 2010; Vincent et al., 2011). The PDAC genome is char-
acterized by a number of signaturemutations involving theKRAS
oncogene and the CDKN2A, TP53, and SMAD4 tumor suppres-
sor genes and by significant chromosomal aberrations resulted
from telomere dysfunction and centrosome abnormalities,
among other mechanisms (Hezel et al., 2006; Jones et al.,
2008; Campbell et al., 2010; Biankin et al., 2012). Activating
mutations in KRAS are present in the majority of human PDAC
cases, and genetically engineered mouse (GEM) models have
substantiated critical roles of oncogenic Kras in driving tumor
initiation and in enabling tumor progression along with defi-
ciencies of P53, Ink4a/Arf, Smad4, and/or Pten tumor suppres-
sors (Aguirre et al., 2003; Guerra et al., 2003; Hingorani et al.,
2003; Tuveson et al., 2004; Bardeesy et al., 2006; Hill et al.,
2010; Ying et al., 2012; Guerra and Barbacid, 2013). The panoply
of signaling pathways engaged by oncogenic Kras provides
a basis for its diverse tumor biological roles in proliferation,
survival, metabolism, and tumor microenvironment remodeling
(Pylayeva-Gupta et al., 2011).
The oncogene addiction and tumor maintenance paradigm
(Weinstein, 2002; McCormick, 2011; Hanahan and Weinberg,
2011) has rationalized the striking clinical responses achieved
with drugs targeting driver oncogenes (Torti and Trusolino,
2011). Despite significant clinical responses to targeted thera-
pies, nearly all tumor remissions are followed by acquired resis-
tance and tumor relapse. Resistance mechanisms vary consid-
erably and include mutations blocking drug-target interaction,
genetic alterations sustaining signaling in downstream path-
ways, or alternate survival pathways (Torti and Trusolino, 2011;
Berns and Bernards, 2012). The pervasive disease recurrence
following targeted therapy has motivated the use of inducibleCell 158, 185–197, July 3, 2014 ª2014 Elsevier Inc. 185
driver oncogene GEM models of cancers to proactively illumi-
nate potential mechanisms of resistance employed by human
cancers (Lauchle et al., 2009).
Given the essential roles of oncogenic Kras in both PDAC initi-
ation andmaintenance, mutant KRAS and its signaling pathways
have been a major focus for the development of disease models
for human PDAC (Hingorani et al., 2003; Collisson et al., 2012;
Collins et al., 2012; Ying et al., 2012; Eser et al., 2013; Guerra
and Barbacid, 2013). To model anti-Ras therapy, we and others
have generated an inducible KrasG12D GEM PDAC model and
established that extinction of KrasG12D induced rapid tumor
regression, highlighting the potential clinical utility of targeting
oncogenic KRAS in pancreatic cancer (Collins et al., 2012;
Ying et al., 2012).
Despite its critical role in PDAC biology, we sought to deter-
mine whether sustained oncogenic Kras suppression would
result in tumor relapse and would illuminate tumor resistance
mechanisms. Employing our previously described doxycycline
(doxy)-inducible KrasG12D GEM PDAC model, we identified
relapse tumors (after KrasG12D extinction induced tumor regres-
sion) that lacked transgene expression and instead harbored
an activated Yap1/Tead2 transcriptional program enabling
KrasG12D-independent tumor cell proliferation that enlists the
cooperative actions of the E2F transcription factor. Interestingly,
our findings in the mouse model are reinforced by observation in
human PDAC showing a prominence of similar transcriptional
programs in the quasimesenchymal subset (QM subset) of
pancreatic cancers, which are notable for lower dependency
on oncogenic KRAS relative to other PDAC subsets (Collisson
et al., 2011).
RESULTS
Spontaneous Pancreatic Tumor Relapse after KrasG12D
Inactivation-Induced Complete Clinical Regression
Using mice engineered with a doxy-inducible KrasG12D trans-
gene and conditional p53 null alleles (p48Cre; tetO_LSL-
KrasG12D; ROSA_rtTA; p53L/+, designated iKras), we and others
established that sustained KrasG12D signaling is essential for
pancreatic tumor maintenance (Collins et al., 2012; Ying et al.,
2012). To evaluate the potential for recurrence mechanisms
following KrasG12D extinction, we utilizedMRI imaging tomonitor
regression of advanced pancreatic tumors measuring at least
8 mm in diameter at the time of doxy withdrawal. Consistent
with previous findings (Collins et al., 2012; Ying et al., 2012),
KrasG12D extinction resulted in complete regression despite sig-
nificant tumor burdens in all animals (n = 28), with virtually no
gross tumor detected by MRI imaging at 3 weeks following
doxy withdrawal (Figure 1A). However, 70% of the mice (20/28)
escaped fromdoxywithdrawal with evidence of relapse between
9 and 47 weeks, with a median survival of 36.6 weeks compared
to 15.4weeks for iKrasmicemaintained on continued doxy treat-
ment (p < 0.0001) (Figure 1B). On the morphological level, in
contrast to the well-differentiated ductal features and predomi-
nant CK19 (ductal marker) positivity of the doxy-induced PDACs
(Figure S1A available online) (Ying et al., 2012), all recurrent tu-
mors exhibited poorly differentiated or sarcomatoid features.
They were devoid of acinar (amylase+) or endocrine markers186 Cell 158, 185–197, July 3, 2014 ª2014 Elsevier Inc.(chromogranin+; CHGA) staining, although some tumors partially
retained scattered CK19 staining (Figures 1C and S1A). Consis-
tent with the development ofmore aggressive phenotypes, distal
metastases to lung or liver were observed in 75% (15/20) of the
animals with recurrent tumors versus 21% (8/38) (p < 0.001) of
those carrying primary tumors (Figures 1C and 1D).
The relapsed tumor lesions were of pancreatic origin, as
demonstrated by the presence of Cre-mediated p53 deletion in
cells cultured from the relapse tumors (Figure S1B). Furthermore,
because the iKras PDACmice do not develop pancreatic tumors
in the absence of doxy induction (Ying et al., 2012), we conclude
that these doxy-independent pancreatic tumors are bona fide tu-
mor relapses of the original primary tumors rather than tumors
formed de novo in the absence of oncogene induction.
Doxy-independent tumor recurrence in this model could
potentially result from doxy-independent activation of the iKras
transgene or from Kras-independent mechanisms. Indeed,
although doxy withdrawal results in loss of KrasG12D expression
and downstream signaling in all primary tumors (Ying et al., 2012;
Figures 1E and S1C), approximately half of relapse tumors
examined exhibited re-expression of the iKras transgene
accompanied with canonical downstream signaling; these tu-
mors were designated hereafter as iKras+ relapse tumors (Fig-
ures 1E–1G and S1C, tumors E-9 to E-16). The remaining tumors
did not express the iKras transgene or hyperactivated endoge-
nous Kras expression and exhibited diminished canonical
downstream signaling; these tumors were designated hereafter
as iKras relapse tumors (Figures 1E–1G, S1C, and S1D, tumors
E-1 to E-8). While displaying similar aggressive histopathological
features, the iKras+ versus iKras relapse tumors were readily
distinguishedmolecularly on the basis of mitogen-activated pro-
tein kinase (MAPK) pathway activity. In contrast to iKras+ tumors,
the majority of iKras tumor lines showed relatively lower phos-
pho-Mek (pMek) and phospho-Erk (pErk) both in vivo and in vitro
(Figures 1G and S1C). Furthermore the iKras tumors did not
show compensatory hyperactivation of AKT pathway, and levels
of phospho-ribosomal protein S6 (pS6) were generally lower
relative to iKras+ tumors (Figure S1C). Thus, although oncogenic
Kras signaling in the primary tumors tightly controls MAPK
pathway activity, recurrence of iKras tumors results frommech-
anisms that do not utilize oncogenic Kras or hyperactivated
MAPK/AKT signaling. Because the wild-type Kras allele remains
intact upon KrasG12D extinction in our model system, the contri-
bution of basal signaling activity fromwild-type Kras or other Ras
family members during tumor relapse remains to be elucidated.
Yap1 Is Amplified in iKras Relapse Tumors and Is
Required for Tumor Growth
Next, we explored the molecular mechanisms underlying spon-
taneous tumor relapse after KrasG12D extinction. Array-based
comparative genomic hybridization (aCGH) revealed that all iK-
ras+ relapse tumors exhibited focal amplificationof theRosa26 lo-
cus rtTA allele, providing a likely basis for doxy-independent re-
expression of the iKras transgene (Figure S2A, chromosome
6q). In iKras relapse tumors, the only recurrent genomic alter-
ation was amplification of chromosome 9qA1 region, encom-
passing 11 genes encoding several metalloproteinases, the tran-
scriptional coactivator Yap1, and the antiapoptotic genes Birc2
Day 0 3 weeks 14 weeks 
off-dox 
Pe
rc
en
t s
ur
vi
va
l 
weeks 
off-dox (8-15w) 
A B 
C D 
E 
F 
pErk 
G 
E-9 
E-10 
E-11 
E-12 
E-1 
E-2 
E-3 
E-4 
iKras Relapse Tumor 
dox
 
R
el
at
iv
e 
ex
pr
es
si
on
 
0 
5000 
10000 
15000 
20000 
25000 
30000 
+ - + - 
E
-1
 
E
-2
 
E
-3
 
E
-4
 
E
-5
 
E
-6
 
E
-7
 
E
-8
 
E
-9
 
E
-1
0 
E
-1
1 
E
-1
2 
E
-1
3 
E
-1
4 
E
-1
5 
E
-1
6 
KrasG12D 
Relapse Tumor iKras 
dox
0 
20000 
40000 
60000 
80000 
+ - + - 
E
-1
 
E
-2
 
E
-3
 
E
-4
 
E
-9
 
E
-1
0 
E
-1
1 
E
-1
2 
Ras Activity 
Figure 1. Spontaneous Pancreatic Tumor
Relapse after Complete Regression upon
KrasG12D Inactivation
(A) Representative MRI scan shows initial tumor
regression (3 weeks) but subsequent relapse
(14 weeks) after doxy withdrawal.
(B) Kaplan-Meier overall survival analysis for iKras;
p53L/+ mice after doxy withdrawal. (On) Mice were
fed with doxy. (Off) Mice with advanced PDAC
were switched to doxy-free water 8–15 weeks
after on doxy and observed for relapse.
(C) Histopathological characterization of the
relapse tumors showing poorly differentiated (i)
or sarcomatoid (ii) relapse tumors, with liver (iii) and
lung (iv) metastasis (denoted by arrow).
(D) Quantitative comparison of histopathological
features between primary and relapse tumors.
(E and F) (E) qRT-PCR for KrasG12D transgene
shows expression in relapse tumors. Data repre-
sented as relative normalized expression. (F)
Measurement of Ras activity in relapse tumors.
Two independent iKras cells were maintained in
the presence (+) or absence () of doxy for 24 hr
and used as controls. Error bars represent SD of
duplicate samples.
(G) The relapse tumors were stained with anti-
bodies against pErk.
See also Figure S1.(cIap1) and Birc3 (cIap2). Of these, only Yap1, Birc2, and Birc3
showed a copy-number-linked increase in gene expression (Fig-
ures 2A–2C and S2D). Further, YAP1 protein was found to be
elevated in iKras relapse tumors bearing the 9qA1 amplicon
(E-1, E-2, and E-5), whereas iKras tumors lacking the amplicon
showed low levels of Yap1 (Figures 2B, 2C, and S2C), pointing
to additional escape mechanisms (see Discussion and Shao
et al., 2014 [this issue of Cell]).
To assess the possible role of Yap1, Birc2 and Birc3 over-
expression in driving growth of the iKras relapse tumors, early
passage primary cultures generated from tumors with and
without the 9qA1 amplicon were monitored for cell growth
following shRNA-mediated knockdown of Yap1, Birc2, or
Birc3. Birc2 or Birc3 knockdown had no impact on cell growth
relative to control shRNA-expressing cells (Figures S2E and
S2F). In contrast, two independent shRNAs targeting Yap1
reduced proliferation in clonogenic assays as well as tumor
growth and tumor cell proliferation (Ki-67, Figure 2G) in Yap1-Cell 158, 185amplified relapse tumors (E-1 and E-2)
but exerted no impact on cells without
Yap1 amplification (E-9 and E-10) (Fig-
ures 2D–2F, S2G, and S2H). Interestingly,
persistent Yap1 knockdown in xenografts
generated from Yap1 shRNA-expressing
cells resulted in resumption of KrasG12D
transgene expression, which coincided
with a modest increase in MAPK activity
and increased tumor cell proliferation,
further underscoring the importance of
activated Kras in PDAC maintenance(data not shown). Together, these genomic and functional
studies strongly support a role for Yap1 amplification-driven
overexpression as a mechanism for KrasG12D-independent
PDAC recurrence.
Enforced Yap1 Expression Enables Tumor Maintenance
upon KrasG12D Extinction in PDAC
To evaluatewhether Yap1 gain of functionwould provide amech-
anism for KrasG12D-independent PDAC growth, we engineered
three independently derived Kras-dependent iKras tumor lines
with wild-type Yap1 or constitutively active Yap1S127A mutant
(S127A mutation prevents Yap1 cytoplasmic sequestration by
Lats; Zhao et al., 2007) constructs and assayed them for
anchorage-independent growth in the absence of doxy (Figures
3A, 3B, and 3B). As shown in Figures 3A and 3B, Yap1 or
Yap1S127A expression along with KrasG12V-expressing cells
dramatically enhanced anchorage-independent growth, whereas
GFP-expressingcontrol cells showedprofound impairmentof cell–197, July 3, 2014 ª2014 Elsevier Inc. 187
Figure 2. Yap1 Is Amplified in iKras Relapse Tumors and Is Required for Tumor Growth
(A) aCGH plots of relapse tumors show that the 9qA1 locus containing Yap1 is focally amplified (denoted by red arrow) in E-1, E-2, and E-5. Normalized log2 ratios
for each probe are plotted.
(B) IHC for Yap1 in relapse tumors. Note the increased Yap1 expression in 9qA1 amplicon+ tumors E-1, E-2, and E-5, but not 9qA1 amplicon tumor E-3.
(C) qRT-PCR for Yap1 in relapse tumors. Relative expression levels normalized to reference gene. Error bars represent SD of the mean.
(D) Representative wells of the clonogenic growth assay upon knockdown of Yap1 by two independent shRNAs primary cultures in Yap1 amplicon+ tumors (E-1
and E-2) and the iKras+ tumors (E-9 and E-10). Nontargeting shRNA (sh_Scr) was used as control. Quantification of cell growth is shown at the bottom. Error bars
represent SD of triplicate wells. ***p < 0.001.
(E) Xenograft tumor growth of cell cultures derived fromE-2 expressing two independent Yap1 shRNA or control shRNA. Tumor volumewasmeasured at the days
indicated, and data shown is representative of results from two independent experiments (n = 5 per group). Error bars represent SD of the mean. **p < 0.01;
***p < 0.001.
(F) IHC for proliferation marker Ki-67 and Yap1 in E-2 xenograft tumors expressing Yap1 shRNA described in (E).
(G) Quantification of IHC staining for Ki-67 displayed as a percentage of cells positive for Ki-67 staining. Error bars represent SD of the mean of five random fields.
***p < 0.001.
See also Figure S2.growth in the absence of doxy. The ability of Yap to drive Kras-
independent cell growth aligns with the ability of enforced Yap1
to complement loss of Kras function in human pancreatic cancer
cell lines (Shao et al., 2014).
These cell-culture-based findings were further substantiated
in vivo by the ability of enforced Yap1 expression to substitute
for KrasG12D activity in tumor maintenance. Specifically, Yap1-,188 Cell 158, 185–197, July 3, 2014 ª2014 Elsevier Inc.Yap1S127A-, and KrasG12V-expressing iKras tumor cells grown
orthotopically (Figure 3C) or subcutaneously (Figure S3A) in
nude mice were able to resist tumor regression upon extinction
of oncogenic Kras and were able to promote tumor growth and
proliferation (as measured by Ki-67 staining, Figure 3D), whereas
GFP-expressing control iKras tumor cells fully regressed upon
doxy withdrawal (Figures 3C and S3A). Additionally, Yap1- or
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Figure 3. Enforced Yap1 Expression
Enables Tumor Maintenance upon KrasG12D
Extinction in PDAC
(A) Representative wells of anchorage-indepen-
dent growth assay demonstrating the ability of
Yap1 or Yap1S127A to substitute for oncogenic
Kras in promoting cell growth of iKras cells.
Growth of Gfp-infected cells was impaired in the
absence of oncogenic Kras.
(B) Quantification of anchorage-independent
growth assay in three independently derived iKras
cells (grown off doxy, KrasG12D off). For each
condition, five random fields were counted. Error
bars represent SD of the mean. ***p < 0.001.
(C) Yap1-mediated bypass of tumor regression
(upon inactivation of KrasG12D) in orthotopic
xenografts generated from iKras cells used in (A).
Mice (n = 10 per group) were kept on doxy for
7 days postimplantation and were then switched
to off doxy. (Top) Tumor growth off doxy was
visualized by bioluminescent imaging at 4 weeks
off doxy except for KrasG12V, for which image is
taken 2 weeks after switching animals off doxy.
Gfp-expressing cells regressed upon KrasG12D
inactivation. (Bottom) H&E staining of representa-
tive tumors is shown. Scale bar, 100 mM.
(D and E) IHC for Ki-67 (D, quantified on the right;
error bars represent SD of themean of five random
fields) and pErk (E). Gfp-expressing tumor 72 hr
after doxy was used as a negative control. Note
the proficient proliferation (as visualized by Ki-67
staining in D) and the lack of MAPK activation
(as visualized by low pErk staining in E) in the
Yap1-expressing tumors.
(F) Signaling status of key RAS effectors in short-
term cultures derived from three independent
Yap1-expressing orthotopic tumors described
in (C).
See also Figure S3.Yap1S127A-expressing iKras cells (using two independently
derived lines) showed Kras-independent tumor growth when
injected into nude mice (Figures S3C and S3D). Furthermore,
shRNA-mediated knockdown of Yap1 or YapS127A dramatically
suppressed proliferation of short-term cultures from these
Yap1-expressing orthotopic tumors (described in Figure 3C),
confirming that the growth of bypassed tumors was indeed
Yap1 dependent (Figures S3E–S3G). Notably, Yap1-bypassed
tumors and early passage derivative cell lines showed lower
MAPK activity when compared to KrasG12V-bypassed tumors.
(Figures 3E, 3F, and S3A). Together, these results indicate
that enforced Yap1 expression can substitute for oncogenic
Kras-driven tumor maintenance and associated tumor cell
proliferation.Cell 158, 185Bypass of KrasG12D Extinction by
Yap Involves Interaction with Tead2
Because Yap1 is a transcriptional coacti-
vator and does not bind directly to DNA,
we sought to determine whether tran-
scription factors known to interact with
Yap1 signaling might mediate its activity.Smad1, p73, Runx2, and Tead transcription factors are all
known to mediate the effects of Yap1 in different contexts
(Zhao et al., 2011; Pobbati and Hong, 2013). Interestingly,
only Tead2 levels were significantly higher in iKras relapse
tumors compared to the iKras+ ones (Figure 4A), and Tead2
physically interacted with endogenous Yap1 in early passage
cultures from primary relapse tumors and in cells derived
from Yap1-bypassed tumors (Figures S4A and Figure 4B),
implicating Tead2 as a candidate transcription factor mediating
Yap1’s activity in our system. In line with this hypothesis, the
TEAD family of transcription factors are genetically and bio-
chemically validated mediators of YAP1’s proliferation-inducing
function (Cao et al., 2008; Zhang et al., 2011; Zhao et al., 2011;
Schlegelmilch et al., 2011), and this established activity is–197, July 3, 2014 ª2014 Elsevier Inc. 189
Figure 4. Interaction of Yap1 with Tead2 Is Critical for Its Ability to Bypass KrasG12D Dependence
(A) qRT-PCR for expression of Tead family of transcription factors (Tead1–4) in iKras and iKras+ relapse tumors. Error bars represent SD of the mean.
***p < 0.001.
(B) Tead2 interacts with Yap1 in Yap1 (Flag-tagged) expressing cells (described in Figure 3C). Input (25%) is used as a reference.
(C) Sustained expression of wild-type Yap1, but not TEAD-binding-defective Yap1 mutants (YapS94A and Yap1D60–89), can promote anchorage-independent
growth of iKras cells off doxy. For each condition, five random fields were counted. Error bars represent SD of the mean. ***p < 0.001.
(D) Mutation in Tead-binding domain of Yap1 (S94A) dramatically decreases the ability of Yap1 or Yap1S127A to substitute for oncogenic Kras in vivo. Repre-
sentative images are shown at 6 weeks off doxy (n = 5 per group).
(E) Representative wells (top) of the clonogenic growth assay upon knockdown of Tead2 by two independent shRNAs in Yap1 (or Yap1S127A) expressing cells
(described in Figure 3C). Quantification of cell growth is shown below. Error bars represent SD of triplicate wells. ***p < 0.001.
(legend continued on next page)
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consistent with the observed robust tumor cell proliferation pro-
file in recurrent tumors (Figure 3C).
We thus performed a series of experiments to test whether
Yap1 exerted its growth effects through Tead2. Mutation in
Tead-binding domain (Tead-binding-defective Yap1S94A and
Yap1D60–89; Figures S4B and S4C) completely abolished the
ability of Yap1 to drive proliferation and substitute for oncogenic
Kras both in vitro (Figure 4C) and in vivo (Figure 4D). Similar
results were obtained using the Yap1S127A/S94A double mutant
(Figures 4D and S4D). These results strongly suggest that
Tead2 is a critical partner of Yap1 in promoting tumor cell growth
in the absence of oncogenic Kras. Next, we sought corrobo-
rating evidence of the importance of Tead2 in mediating Yap1
function by directly blocking its activity using two complemen-
tary approaches.
First, shRNA-mediated knockdown of Tead2 reduced the
proliferation of early passage cultures derived from orthotopic
Yap1-bypassed tumors, whereas Tead2 knockdown had no
effect on the KrasG12D-expressing iKras lines (Figures 4E and
S4E). Furthermore, overexpression of a previously characterized
dominant-negative Tead2 mutant (Tead2DN; Liu-Chittenden
et al., 2012), which harbors a deletion of the C-terminal Yap1-in-
teracting domain while retaining the ability to bind DNA, strongly
blocked tumor cell proliferation of Yap1-expressing cells in
clonogenic assays (Figures 4F and S4F). In this case as well,
growth-suppressive activity of Tead2DN is specific to Yap1-ex-
pressing cells, as overexpression of Tead2DN did not suppress
cell proliferation induced by oncogenic Kras (Figure 4F).
Second, we examined whether increasing Tead2 levels could
mimic the effect of Yap1 overexpression. Overexpression of
full-length Tead2 did not promote anchorage-independent cell
growth or orthotopic tumor growth, consistent with a lack of
intrinsic transactivation activity of Tead2 (data not shown). How-
ever, expression of a transcriptionally active form of Tead2,
Tead2-VP16 (a fusion protein of the N-terminal region of Tead2
containing the TEA domain and the activation domain of herpes
simplex virus VP16; Ota and Sasaki, 2008), in two independent
iKras cells promoted orthotopic tumor growth (Figures 4G and
S4G), in the absence of KrasG12D expression. Together, these
multiple lines of evidence establish a critical role for TEAD2 in
mediating Yap1-driven tumor cell growth upon KrasG12D extinc-
tion in our model system.
Yap1/Tead2 Complex Acts Cooperatively with E2F
Transcription Factors to Activate a Cell Cycle and DNA
Replication Program
Next, transcriptomic analyses were conducted to elucidate the
molecular network of Yap1 actions that facilitate KrasG12D-inde-
pendent tumor growth.We defined the baseline gene expression
upon extinction of oncogenic Kras and subsequently compared
this expression profile to that in Yap1-bypassed tumors. To sur-
mise molecular pathways associated with Yap1 overexpression,(F) Dominant-negative Tead2 (Tead2DN) selectively suppresses proliferation of Ya
Quantification of cell growth is shown below. Error bars represent SD of triplicat
(G) The transcriptionally active form of Tead2 (Tead2-VP16) can substitute oncoge
off doxy (n = 5 per group).
See also Figure S4.we performed gene set enrichment analysis (GSEA) of the
expression profiles using gene sets for the canonical pathways
in the Molecular Signature Database (MSigDB) (Subramanian
et al., 2005). Consistent with our tumor biological observations,
GSEA indicated that a significant fraction of KrasG12D-depen-
dent gene sets that are rescued in the Yap1-bypassed tumors
related to cell proliferation, DNA synthesis, and replication (Fig-
ures 5A–5C). We validated several of the differentially expressed
genes by qRT-PCR, including mitotic kinases (including aurora
kinase A [Aurka] and aurora kinase B [Aurkb]), budding uninhib-
ited by benzimidazoles (Bub1), cyclins (including Ccna2,
Ccnb1, Ccnb2, and Ccnd1), cell-division-associated proteins
(including Cdc2, Cdc20, and Cdc25c), and DNA replication
proteins (including minichromosome maintenance complex pro-
teins Mcm5, Mcm6, and Mcm10).
Our findings are in agreement with the known role of Yap1 in
regulating normal cell proliferation through a Tead-mediated
transcriptional program (Ota and Sasaki, 2008; Zhao et al.,
2008; Schlegelmilch et al., 2011; Zhang et al., 2011; von Gise
et al., 2012; Xin et al., 2013). Indeed, several bona fide Yap1
target genes, including Ccnd1 and Birc5, were documented to
be upregulated in Yap1-bypassed tumors. Together, these ana-
lyses support the view that Yap1 enables tumor growth upon
KrasG12D extinction through the coordinate activation of genes
governing cell cycle and DNA replication.
It has been suggested that Yap/Tead-mediated gene regula-
tion may rely on a combinatorial network of transcription factors
to drive gene expression thresholds (Nicolay et al., 2011). To
determine whether Yap/Tead cooperates with a particular tran-
scription factor in a coordinated gene expression program, we
performed promoter analysis and identified several transcription
factor motifs, including E2F, several members of the ATF family
(activating transcription factors), and CREB1 (cyclic-AMP
response element binding protein 1) enriched in the promoters
of differentially expressed genes in Yap1-bypassed tumors (Fig-
ure 5D and data not shown).We focused further study on the E2F
family of transcription factors, as recent studies in Drosophila
have emphasized that E2f1 is required for the full activation of
specific target genes by fly Yap1 and Tead orthologs Yki and
Sd (Nicolay et al., 2011).
To assess a potential cooperative role of E2F in Yap1/Tead2-
mediated bypass of tumor regression, we first sought to deter-
mine co-occurrence of TEAD- and E2F-binding sites among
the differentially expressed genes in the Yap1-bypassed tumors.
Using the TRANSFAC position frequency matrix, we found sig-
nificant enrichment for genes containing putative binding sites
for both Tead and E2F specifically in the promoters of genes
that were upregulated (2-fold upregulated, p < 0.005) in the
Yap1-bypassed tumors (19/241; p < 0.05). Using chromatin
immunoprecipitation (ChIP), we next validated occupancy of
E2F1 along with YAP1 (Flag-tagged)/TEAD2 (V5-tagged) at pro-
moters of several representative genes with predicted E2F- andp1 (or Yap1S127A) expressing cells, but not the KrasG12D-expressing iKras cells.
e wells. ***p < 0.001.
nic Kras for in vivo tumor growth. Representative images are shown at 6 weeks
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TEAD-binding sites and showed no occupancy in an intergenic
region lacking any putative E2F/TEAD-binding sites (Figure 5E).
We further validated occupancy of endogenous Yap1 at three
representative loci in early passage cultures derived from Yap1
amplicon-positive tumors (E-1 and E-2), but not Yap1 ampli-
con-negative (E-3) tumor (Figure S5). As a specificity control, a
nonspecific IgG antibody failed to immunoprecipitate any of
the above promoter fragments (Figure 5E). These in silico and
ChIP analyses support the view that E2f cooperates with Yap1/
Tead2 in coordinating downstream gene expression.
Next, to assess the functional importance of E2F binding,
we blocked E2F activity utilizing a dominant-negative form of
E2F1 (E2F1DN) that lacks the transactivation domain (Adams
and Kaelin, 1996). Expression of the dominant-negative E2F1
suppressed proliferation of Yap1-expressing cells (Figure 5F),
supporting a role for E2F1 activity in enabling Yap1/Tead2-medi-
ated bypass of tumor regression upon KrasG12D extinction.
KrasG12D-Independent Relapse Tumors Resemble QM
Subtype of Human PDAC
As noted, a subset of human PDAC cell lines becomes less
dependent on oncogenic KRAS (Singh et al., 2009). To assess
the potential clinical relevance of our Kras-independent relapse
PDAC tumors, we compared the transcriptomic profiling of the
relapse tumors with those reported in primary human PDACs
and PDAC cell lines (Collisson et al., 2011). As a control, we
also performed transcriptomic analysis of doxy-induced iKras
PDAC lines. When subjected to unbiased clustering analysis,
5 of 8 iKras relapsed tumor profiles clustered closely with
each other, and 5 of 8 iKras+ relapse tumors clustered with the
doxy-induced primary PDAC lines (Figure 6A), reinforcing the
view that iKras relapse tumors are molecularly distinct from
KrasG12D-dependent tumors.
Human PDAC was recently defined into three subtypes based
on transcriptional profiles: classical, quasimesenchymal, and
exocrine-like, which correspond with distinctive clinical outcome
and therapeutic responses (Collisson et al., 2011). Six out of ten
KrasG12D-positive tumors, including the doxy-induced iKras lines
and the iKras+ relapse tumors, show expression signatures of
classicalPDAC,whicharehighly linked tooncogenicKrasactivity.
In contrast, five of eight iKras lines clusteredwithQMsubtype of
humanPDAC,which have been reported to showhighexpression
of mesenchymal genes, lower KRAS expression, and less KRAS
dependency (Figure 6A; Collisson et al., 2011). The fact that we
see a statistically significant association between iKras relapse
tumors and the quasimesenchymal subtype of human PDAC
aligns well with the observation that these human tumors tend(B) Representative GSEA enrichment plots showing overrepresentation of indica
compared with Gfp-expressing tumors (24 hr, off doxy). NES denotes normalize
(C) qRT-PCR validation of representative differentially expressed genes in Yap-e
(D) GSEA enrichment plots showing E2Fmotif containing gene signatures in the dif
(E) ChIP showing YAP1 and TEAD2 occupancy at E2F1-bound promoters of se
region (lacking any putative E2F/TEAD binding sites). IgG served as a specificit
promoter relative to the 30 region of each gene. Error bars represent SD of the m
(F) Dominant-negative E2F1 (E2F1DN) suppresses proliferation of Yap1 (or Yap1S1
on the right. Error bars represent SD of triplicate wells. ***p < 0.001.
See also Figure S5.to be less KRAS dependent (chi-square test, p = 0.01). Interest-
ingly, Shao et al. (2014) demonstrated that a YAP/FOS-mediated
epithelial-to-mesenchymal transition (EMT) program can also
drive KRAS-independent tumor growth, further corroborating
the relationship between KRAS independence and Yap1 as well
as underscoring the complexity of Yap1 signaling.
To gain insight into whether YAP1 might have a role in driving
growth of human Kras-independent PDAC, we first compared its
expression in previously established human Kras-dependent
and Kras-independent PDAC cells (Singh et al., 2009; Collisson
et al., 2011). In line with our murine findings, YAP1 expression
was significantly higher in the human KRAS-independent
PDAC cells (Figure 6B). Next, to determine whether YAP1 is
required for growth of QM KRAS-independent subtype cells,
we performed knockdown of YAP1 in two KRAS-independent
QM human PDAC cell lines (Panc1 and PaTu8988T) and one
wild-type KRAS cell line BxPC-3 (Figures 6C and 6D). shRNA-
mediated knockdown of YAP1 strongly suppressed the prolifer-
ation of these cells, implying that YAP1 is indeed essential for
their growth (Figure 6D). Together, our data indicate that the
oncogenic Kras-independent relapse tumors tend to resemble
the QM subtype of human PDAC and rely on alternative onco-
genic mechanisms, including Yap1, for their growth.
DISCUSSION
In this study, we investigated potential resistance mechanisms
to oncogenic Kras extinction in the context of significant tumor
burden. Following oncogenic Kras extinction and complete
tumor regression in all animals, approximately one-third of the
animals indeed remained tumor free over a period of up to
65 weeks. This observation, together with re-expression of the
iKras transgene in approximately half of the mice with tumor
recurrence, emphasizes the prominent role of oncogenic Kras
in tumor maintenance. Tumor recurrence following complete
extinction of oncogenic Kras was not anticipated, given the
wide spectrum of critical pathways controlled by Kras in cancer.
At the same time, our work and that of Shao et al. (2014) demon-
strate the potential for oncogenic Kras-independent bypass
mechanisms involving the Yap1 oncogene, emphasizing that
PDAC tumor cells can survive in the absence of oncogenic
Kras signaling and can acquire alternative mechanisms to foster
their own growth, portending the need for anti-Yap1 therapeutic
strategies for some tumors in the setting of agents targeting Kras
and its signaling pathways.
Our results have important ramifications in anticipating clinical
responses in drugs designed directly to target oncogenic Kras.ted gene set categories among differentially expressed genes in Yap1 tumors
d enrichment score.
xpressing tumors. Error bars represent SD of duplicate samples.
ferentially expressed genes in Yap1-expressing tumors comparedwith control.
veral representative genes. No occupancy was seen in the control intergenic
y control for the antibody. Bars represent enrichment at target regions in the
ean.
27A) expressing cells. Quantification from a representative experiment is shown
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Figure 6. KrasG12D-Independent Relapse Tumors Resemble the Quasimesenchymal Subtype of Human PDAC
(A) Hierarchical clustering of murine PDAC iKras cells and the relapse tumors into different PDAC subtypes using PDAssigner genes (Collisson et al., 2011).
Subtype analysis found statistically significant association between iKras relapse tumors and the QM subtype, whereas the iKras+ tumors are associated with
the classical subtype (chi-square test, p = 0.01; Collisson et al., 2011). The subtype identity of the samples (in gray) is not apparent.
(B) Gene expression data reanalyzed from Collisson et al. (2011) showing that YAP1 expression is significantly higher in the Kras-independent lines compared to
Kras-dependent human PDAC cells. The y axis indicates gene expression data expressed as log2 median centered intensity. Boxed bars indicate the medians.
(C) Western blots validating the knockdown of YAP1 in the indicated human PDAC cell lines by two independent shRNAs.
(D) Representative wells (top) of clonogenic growth of Kras-independent QM human PDAC cells (Panc1 and PaTu8988T) and the wild-type KRAS cell line BxPC-3
upon YAP1 knockdown. Quantification (bottom) from a representative experiment is shown on the right. Error bars represent SD of triplicate wells. ***p < 0.001.Based on this study and resistance mechanisms discovered in
response to other targeted therapies, at least three distinct resis-
tance mechanisms against Kras extinction are possible. First,
genomic alterations can act on target itself, driving relapse by
circumventing target blockade. This is supported by our obser-
vation that, in approximately half of the relapse tumors, the iKras
transgene is amplified. Second, augmentation of key growth194 Cell 158, 185–197, July 3, 2014 ª2014 Elsevier Inc.signaling pathways through activation of compensatory path-
ways may induce tumor relapse. In agreement with such a
notion, Shao et al. showed that expression of receptor tyrosine
kinases bypass the dependency on oncogenic Kras. Our prelim-
inary gene expression data raise the intriguing possibility of
activation of multiple RTKs and/or their ligands in Yap1 ampli-
con-negative relapse tumors (E-3, E-4 and E6-E8; data not
shown). Third, and most importantly, we and Shao et al., have
uncovered a novel mechanism of resistance to Kras inhibition
through a Yap1-mediated transcriptional program. Amplification
of Yap1 in our study is reminiscent of classic second-site sup-
pression events that substitute for critical functions of oncogenic
Kras, particularly tumor cell proliferation, thus allowing Kras-
dependent tumors to escape dependency on oncogenic Kras.
Yap1, a transcriptional coactivator and the downstreammedi-
ator of Hippo signaling, is regulated posttranscriptionally by
either kinase-mediated degradation or cytoplasmic sequestra-
tion (Harvey et al., 2013; Zhao et al., 2011). Yap1 is known to
be involved in cell proliferation, epithelial-to-mesenchymal
transition, invasion, and metastasis. Notably, recurrent amplifi-
cations of Yap1 locus 11q22 have been observed in liver carci-
noma, oral squamous cell carcinomas, medulloblastomas, and
esophageal cancer (Zender et al., 2006; Snijders et al., 2005;
Fernandez-L et al., 2009; Muramatsu et al., 2011). Our findings
indicate that Yap1 is sufficient for driving PDAC recurrence
upon Kras withdrawal in the iKras model, previously character-
ized for its dependence on oncogenic Kras signaling for tumor
initiation, progression, and maintenance. However, Yap1 ap-
pears to be insufficient to drive de novo PDAC development,
as pancreas-specific inactivation of the Mst1/2 kinases and
associated Yap1 activation and enhanced cell proliferation fail
to initiate tumor formation (George et al., 2012; Gao et al.,
2013). Several mechanisms might underlie the differences
observed in iKras tumor recurrence and in pancreas-specific
deletion of Mst1/2, including the presence of intact tumor sup-
pressor pathways or the absence of transcription factor media-
tors in the latter study.
In our study, Tead2 is required for Yap1-mediated tumor
relapse. Interestingly, Tead2 has been shown to play an
important role in stem cell maintenance and in self-renewal
(Cao et al., 2008; Tamm et al., 2011), and thus we speculate
that residual surviving tumor cells or tumor stem cells following
Kras extinction maintain their viability in a Tead2-dependent
manner. This rare subpopulation of PDAC cells may be enriched
for tumor-initiating activity and may be capable of surviving ge-
netic or pharmacological inactivation of Kras and its surrogates.
Such surviving cells could provide a reservoir of relapsed tumor
cells to enable acquisition of Kras-independent tumor mainte-
nance events. In support of this hypothesis, we have generated
preliminary data showing Tead2 is highly expressed and is
important for survival of a subpopulation of tumor cells that sur-
vive KrasG12D extinction (A.K., A.V., et al., unpublished data). It is
not clear, however, whether YAP1 amplification is already pre-
sent in these rare oncogene-independent cells before KrasG12D
ablation or whether it is acquired after oncogene extinction.
Further work using clonal tracking methodologies would be
needed to define the relationship between these surviving cells
and the relapse tumors seen in our model.
The findings that Yap1 can substitute for oncogenic Kras
in advanced PDAC raise the possibility that Yap1 can similarly
substitute for activated RAS in other malignancies or in other
cellular contexts. In agreement with this supposition, Shao
et al. (2014) identified Yap1 in a gain-of-function screen to iden-
tify genes that can substitute for Ras signaling in KRAS-depen-
dent human cancer cells. Consistent with the pleiotropic effectsof Yap1, both studies converge on overlapping networks, such
as ATF and E2Fs, and diverge on distinct transcriptional pro-
grams, such as Tead2 (this study) and Fos (Shao et al., 2014).
Our convergent and contrasting findings are consistent with
the established fact that the Yap1-mediated gene expression
program is largely dictated by the cellular context and its inter-
acting transcription factors (Pobbati and Hong, 2013; Zhao
et al., 2011).
Interestingly, the iKras relapse tumors display features
similar to the QM subtype of human PDACs associated with
poor prognosis (Collisson et al., 2011). Although YAP1-amplified
tumors clearly fall into the nonclassical subtype, the limited num-
ber of tumors prevents us fromdefinitely subgrouping the tumors
with YAP1 amplification. However, the significant correlation
between iKras status and classical/QM subtypes aligns with
previously published results showing that Kras dependency is
strongly linked to epithelial differentiation status and that, upon
EMT, Kras dependency is reduced in human cancer cells (Singh
et al., 2009). Furthermore, the observation by Shao et al. that
YAP1 can replace oncogenic Kras in part by regulating an
EMT-like program further supports the link between EMT status,
Kras independence, and Yap1 expression and also underscores
the complexity of Yap1 signaling.
Future studies should be encouraged to examine the role of
Yap1 in the recently defined QM subset in human PDAC, which
is notably less dependent on oncogenic Kras. The continued
development of small molecules targeting Yap1 that have
delayed tumor progression in mouse models of liver cancer
(Liu-Chittenden et al., 2012; Stanger, 2012) may prove useful in
human PDAC subtypes with elevated Yap1 expression.
EXPERIMENTAL PROCEDURES
Transgenic Mice
TetO_Lox-Stop-Lox-KrasG12D (tetO_LKrasG12D), ROSA26-LSL-rtTA-IRES-
GFP (ROSA_rtTA), p48-Cre, and Trp53L strains were described previously
(Ying et al., 2012). Mice were interbred and maintained on FVB/C57Bl6 hybrid
background in pathogen-free conditions at M.D. Anderson Cancer Center.
Mice were fed with doxy water (Doxy 2g/l in sucrose 20 g/l). All manipu-
lations were approved under MD Anderson Cancer Center (MDACC) Institu-
tional Animal Care and Use Committee (IACUC) under protocol number
111113931.
In Vivo Imaging
All in vivo imaging was performed at the Small Animal Imaging Facility at
MDACC. MRI was performed weekly using a 4.7T Bruker Pharmascan. For
bioluminescent imaging, animals were anesthetized with isoflurane, injected
intraperitoneally with 3 mg of D-Luciferin (Perkin Elmer), and imaged using
IVIS Spectrum Imaging System (Perkin Elmer). The Living Image 4.3 software
(Perkin Elmer) was used for analysis of the images postacquisition.
Xenograft Studies
All xenograft studies were carried out in NCr nude mice (Taconic) and were
approved by the MD Anderson IACUC under protocol number 111113931.
Details of the subcutaneous and orthotopic xenograft studies are listed in
Extended Experimental Procedures.
Array-CGH Profiling and Analyses
For Array-CGH, genomic DNA processing (from tumor and matched tail DNA),
labeling, and hybridization to Agilent custom 415K mouse CGH array (Agilent
Design ID 025735, NCBI GEO ID:- GPL15058) were performed as per the
manufacturer’s protocol (Agilent).Cell 158, 185–197, July 3, 2014 ª2014 Elsevier Inc. 195
Lentivirus-Mediated shRNA Knockdown
All lentiviral shRNA clones targeting Yap1, Tead2, Birc2, Birc3, and nontarget-
ing shRNA control were obtained from Sigma Aldrich in the pLKO vector (Mof-
fat et al., 2006). The TRC IDs for the shRNA used in the study are listed in the
Extended Experimental Procedures.
Immunohistochemistry and Western Blot Analysis
Tissueswere fixed in 10% formalin overnight and embedded in paraffin. Immu-
nohistochemical (IHC) analysis was performed as described earlier (Aguirre
et al., 2003). For western blot analysis, cells were lysed on ice using RIPA
buffer (Boston BioProducts) supplemented with protease and phosphatase in-
hibitors (Roche). Primary antibodies used for immunohistochemistry (IHC) and
western blot analysis are listed in the Extended Experimental Procedures.
Gene Expression Profiling and Subtype Analysis
Gene expression profiling was performed using Affymetrix Gene Chip Mouse
Genome 430 2.0 Arrays. Details on mRNA expression profiling and data anal-
ysis are described in the Extended Experimental Procedures.
Statistical Analysis
Tumor volume and tumor-free survivals were analyzed using GraphPad Prism.
To assess distributional differences of variance across different test groups,
the Mann-Whitney test was used. Other comparisons were performed using
the unpaired Student’s t test. For all experiments with error bars, standard de-
viation (SD) was calculated to indicate the variation with each experiments and
data, and values represent mean ± SD.
ACCESSION NUMBERS
The GEO accession number for the microarray data reported is GSE53169.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at http://dx.doi.org/10.
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